Conventional Blood Testing
Unlike current blood testing methods, the pathogen inactivation achieved by the INTERCEPT Blood System is not limited to particular nucleic acid sequences or specific families of pathogens. Consequently, INTERCEPT can potentially inactivate emerging pathogens for which there is currently no screening or testing. Pathogen inactivation also has the potential to reduce transfusion-transmitted related adverse events, which can be expensive to treat and dangerous to transfusion recipients. Conventional blood tests rely upon advance identification of known viruses, or crude, time consuming and imprecise tests for bacteria and parasites, which leaves the blood supply vulnerable to emerging pathogens until tests are developed, approved and deployed.